Idarubicin
Idarubicin is an anthracycline antileukemic medication renowned for its significant role in managing various forms of leukemia. As a derivative of daunorubicin, this molecule exhibits increased lipophilicity, which expedites its cellular uptake. Notably, its mechanism hinges on DNA interaction and consequential obstruction of the enzyme topoisomerase II.
Chemical Characteristics[edit]
Idarubicin, or 4-demethoxydaunorubicin, is distinguishable from daunorubicin due to its absent methoxy group. This structural deviation accentuates its lipophilic traits, boosting cellular absorption[1].
Mechanism of Action[edit]
Its antileukemic activities are ascribed to several interconnected mechanisms:
- DNA Interaction: Idarubicin integrates with DNA, obstructing the DNA's inherent flexibility.
- Topoisomerase II Inhibition: It impedes the enzyme topoisomerase II, blocking the unwinding of DNA strands[2].
- Histone Eviction: Like other anthracyclines, idarubicin induces histone removal from chromatin, potentially modulating gene expression.
Therapeutic Use[edit]
Categorized within antitumor antibiotics, its clinical implications comprise:
- Synergy with cytosine arabinoside for first-line treatment against acute myeloid leukemia (AML)[3].
- Addressing acute lymphoblastic leukemia (ALL).
- Intervention in Chronic myelogenous leukemia (CML) during its blast crisis phase.
Trade names differ based on regional availabilities:
- Zavedos in the UK
- Idamycin in the USA[4].
Adverse Effects[edit]
Treatment recipients might encounter several side effects, common ones being:
- Diarrhea
- Stomach cramps
- Nausea
- Vomiting
Healthcare practitioners should closely monitor these signs to ensure patients' comfort and therapy compliance.
Conclusion[edit]
Idarubicin remains a linchpin in leukemia treatment. Its distinct mode of action and established efficacy afford patients grappling with these blood malignancies a beacon of hope. Yet, the pivotal task remains to juxtapose its therapeutic advantages with potential adverse events, ensuring paramount patient care.
References[edit]
- ↑ Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004 Jun;56(2):185-229.
- ↑ Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol. 1994 May;45(5):649-56.
- ↑ Wiernik PH, Banks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992 Jan 15;79(2):313-9.
- ↑ Thomas X, Archimbaud E. Idarubicin in the treatment of acute myeloid leukemia. Cancer Treat Rev. 1997 Oct;23(5-6):257-66.
 | This medical article is a stub. You can help WikiMD by expanding the page. |
